New Drugs Available for Fabry Disease

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Fabry disease (FD) is an X-linked genetic disorder caused by GLA gene variants, leading to α-galactosidase A (α-Gal A) deficiency.
• This deficiency results in the accumulation of glycosphingolipids, primarily affecting the cardiovascular, renal, and nervous systems and reducing life expectancy.
• Optimal treatment initiation and dosage are critical for improving outcomes and quality of life in FD patients.

Purpose of the Study:

• To review newly available drugs and future therapeutic approaches for Fabry disease.
• To highlight the benefits and limitations of current and emerging FD treatments.
• To discuss the potential of novel therapies in enabling individualized care for FD patients.

Main Methods:

• Review of current literature on Fabry disease treatments.
• Analysis of novel therapeutic agents including migalastat, pegunigalsidase alfa, substrate reduction therapy (SRT), and gene therapy.
• Examination of clinical trial data and preclinical studies for emerging therapies.

Main Results:

• Migalastat offers oral administration and non-immunogenicity but is suitable only for patients with amenable GLA variants.
• Pegunigalsidase alfa, a plant cell-cultured enzyme, shows reduced immunogenicity and a prolonged half-life.
• SRT agents (venglustat, lucerastat) reduce Gb3 synthesis, are orally administered, non-immunogenic, and may cross the blood-brain barrier.
• Gene therapy approaches (ex vivo and in vivo) are under investigation with positive early outcomes in human and animal studies.

Conclusions:

• Ongoing development provides a wider array of therapies for individualized Fabry disease care.
• While a definitive cure is not yet available, new options like gene and mRNA-based treatments show promise.
• Further research is necessary to overcome challenges such as treatment costs and to fully realize the potential of novel therapeutic strategies.